Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial)

Journal of the American College of Cardiology

Volumn 40, Issue 4, 2002, Pages 662-668

  Bonz, Andreas W ^a   Lengenfelder, Björn ^a   Strotmann, Jörg ^a   Held, Stefanie ^a   Turschner, Oliver ^a   Harre, Kerstin ^a   Wacker, Christian ^a   Waller, Christiane ^a   Kochsiek, Nikolaus ^a   Meesmann, Malte ^a   Neyses, Ludwig ^a   Schanzenbächer, Peter ^a   Ertl, Georg ^a   Voelker, Wolfram ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR; GLYCOSIDE; NITRATE; TIROFIBAN; TROPONIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVASCULARIZATION; STROKE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREMEDICATION; STENTS; SURGICAL PROCEDURES, ELECTIVE; TICLOPIDINE; TROPONIN T; TYROSINE;

EID: 0037151685     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02014-4     Document Type: Article

References (37)

1. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation
2. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
3. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
4. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction
5. Clinical implications of the "no reflow" phenomenon: A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction
6. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of glycoprotein IIb/IIIa blockade
7. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
8. Effect of platelet GP IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
9. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrillin therapy (PURSUIT) trial
10. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
11. Cardiac troponin T, creatine-kinase, and its isoforms release after successful percutaneous transluminal coronary angioplasty with or without stenting
12. Significance of cardiac troponin release after percutaneous transluminal coronary angioplasty
13. Clinical outcome after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention
14. Cardiac troponin T levels for risk stratification in acute myocardial ischemia
15. Rapid platelet-function assay: An automated and quantitative cartridge based method
16. Point of care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention
17. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary interventions
18. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
19. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
20. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity
21. Significance of mild transient release of creatin-kinase MB-fraction after percutaneous coronary interventions
22. Troponin T and myocardial damage
23. The myth of the myocardial "infarctlet" during percutaneous coronary revascularisation procedures
24. S-troponin-T as a marker of ischemic myocardial injury
25. Minimal myocardial damage during coronary intervention is associated with impaired outcome
26. Prognostic significance of myocardial enzyme release after coronary interventions
27. Prognostic implication of creatine kinase elevation following elective coronary artery interventions
28. Cardiac troponin T and CKMB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris
29. Troponin T, troponin I and creatine kinase-MB mass after elective coronary stenting
30. Myocardial infarction redefined
31. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements
32. Platelet function in acute myocardial infarction treated with direct angioplasty
33. Percutaneous interventions in patients with prior bypass surgery
34. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death
35. Coronary thrombosis, ulcerated atherosclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: A large autopsy study
36. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation
37. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: A randomized controlled trial